SHSanling Huang

Sanling Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sanling Huang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chuan-Yun Li

    State Key Laboratory of Protein and Plant Gene Research, Laboratory of Bioinformatics and Genomic Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University , Beijing 100080

    1 shared publication
  • Chuanhui Han

    Peking University-Yunnan Baiyao International Medical Research Center, Peking University International Cancer Institute, Beijing, 100191, China

    1 shared publication
  • Chunfu Xiao

    State Key Laboratory of Protein and Plant Gene Research, Laboratory of Bioinformatics and Genomic Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China

    1 shared publication
  • Di Wang

    BGI Research, Beijing, China.

    1 shared publication
  • Fan Wang

    State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences , Beijing 100101

    1 shared publication
  • Fei Du

    BGI Research 3 , Beijing

    1 shared publication

Latest Publications

  • Tumors with microsatellite instability upregulate TREX1 to escape antitumor immunity

    by Yan Xu, Zheqi Zhou, Wenzheng Chen, Fei Du, Sanling Huang, Jinhui Qi, Yuwen Zeng, Hao Su, Jiaxin Wang, Chunfu Xiao, et al.

    Currently, it remains largely unclear how MSI-H/dMMR tumors, despite heightened immune pathway activation and antigenic mutation accumulation, evade immune elimination and promote tumorigenesis. Our study showed that dMMR tumors accumulate cytosolic double-stranded DNA, activating the cGAS–IFN pathway and upregulating DNA-digesting enzyme TREX1. In immunocompetent mice, Trex1 depletion in MSI-H/dMMR tumors abolished tumor formation in a CD8+ T cell–dependent manner, suggesting its critical role in enabling these tumors to evade immune attack. Mechanistically, Trex1 loss amplified tumor-intrinsic cGAS–STING signaling, promoted the activation of CD8+ T cells, and triggered systemic antitumor immunity. Critically, ablating cGAS–STING signaling in MSI-H/dMMR tumors abolished the immune boost from TREX1 deletion, revealing the critical role MSI-H/dMMR tumor-intrinsic cGAS–STING pathway. Furthermore, Trex1 inhibition specifically reduced MSI-H/dMMR tumors growth in vivo, highlighting its clinical potential. Together, we identify the cGAS–STING-TREX1 loop as a key immune escape mechanism in MSI-H/dMMR cancers, suggesting TREX1 inhibition could enhance immunotherapy for these patients.